PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection (TUM2P.881)
| Autor: | Alexander MacFarlane, Mowafaq Jillab, Elizabeth Plimack, Gary Hudes, Robert Uzzo, Samuel Litwin, Essel Dulaimi, Tahseen Al-Saleem, Kerry Campbell |
|---|---|
| Rok vydání: | 2014 |
| Předmět: | |
| Zdroj: | The Journal of Immunology. 192:71.5-71.5 |
| ISSN: | 1550-6606 0022-1767 |
| DOI: | 10.4049/jimmunol.192.supp.71.5 |
| Popis: | In this study, we analyzed expression of numerous immune cell markers on fresh PBMC from 90 RCC patients preoperatively and 25 age-matched healthy controls by 10-color flow cytometry. Postoperative blood samples were also analyzed from 23 members of the RCC patient cohort. The most striking phenotypic immune biomarker in RCC patients was a significant increase in PD-1 expression on certain PBMC in a subset of patients. Increased PD-1 expression on CD14bright myelomonocytic cells, effector T cells, and NK cells correlated to disease stage. Importantly, we also observed that expression was significantly reduced on all cell types in virtually all patients within 2 weeks after surgical resection of the primary tumor. Based upon our results, we conclude that PD-1 expression on fresh peripheral blood leukocytes may provide a useful indicator of RCC disease progression. Furthermore, measuring PD-1 levels in peripheral blood may assist in identifying patients likely to respond to PD-1 blocking antibodies, and these therapies may be most effective before and immediately after surgical resection of the primary tumor, when PD-1 expression is most prominent. Finally, we conclude that long-term PD-1 blocking therapy after nephrectomy may only be effective in stage 3 and stage 4 patients that retain PD-1 expression, presumably maintained by the presence of residual metastatic tumor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|